Seeking Alpha

Navidea Biopharmaceuticals (NAVB +2.3%) is set to close higher after announcing that the...

Navidea Biopharmaceuticals (NAVB +2.3%) is set to close higher after announcing that the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing intends to switch to using NAVB's Fluorine-18 labeled amyloid imaging candidate, NAV4694, for its research initiative on Alzheimer's disease and mild cognitive impairment.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|